- Bloomberg•26 days ago
Valeant Pharmaceuticals International Inc.’s Relistor drug has attracted interest from other companies as the beleaguered Canadian firm works to reduce its debt load, people familiar with the matter said....
- Associated Press•27 days ago
The Tarrytown, New York-based company said it had a loss of 8 cents per share. The biopharmaceutical company posted revenue of $8.5 million in the period. Progenics shares have decreased nearly 5 percent ...
- GlobeNewswire•27 days ago
On July 19, the Company Announced FDA Approval of RELISTOR ® Tablets, Triggering a $50 Million Milestone Ultra-Orphan Radiotherapeutic Candidate AZEDRA ® Registrational Trial Topline Results Expected Between ...
Progenics Pharmaceuticals, Inc. (PGNX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||6.01 x 100|
|Ask||6.98 x 300|
|Day's Range||6.40 - 6.67|
|52wk Range||3.61 - 8.37|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-12.70|
|Avg Vol (3m)||1,582,878|
|Dividend & Yield||N/A (N/A)|